ATE334973T1 - Chinazolinverbindungen - Google Patents
ChinazolinverbindungenInfo
- Publication number
- ATE334973T1 ATE334973T1 AT01921530T AT01921530T ATE334973T1 AT E334973 T1 ATE334973 T1 AT E334973T1 AT 01921530 T AT01921530 T AT 01921530T AT 01921530 T AT01921530 T AT 01921530T AT E334973 T1 ATE334973 T1 AT E334973T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- aromatic
- ring
- saturated
- quinazoline compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00400968 | 2000-04-07 | ||
EP00400967 | 2000-04-07 | ||
EP00401033 | 2000-04-13 | ||
EP00401034 | 2000-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE334973T1 true ATE334973T1 (de) | 2006-08-15 |
Family
ID=27440054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01921530T ATE334973T1 (de) | 2000-04-07 | 2001-04-03 | Chinazolinverbindungen |
Country Status (20)
Country | Link |
---|---|
US (2) | US7160889B2 (de) |
EP (1) | EP1274692B1 (de) |
JP (2) | JP4970689B2 (de) |
KR (1) | KR100858069B1 (de) |
CN (1) | CN1240688C (de) |
AT (1) | ATE334973T1 (de) |
AU (1) | AU779695B2 (de) |
BR (1) | BR0109828A (de) |
CA (1) | CA2403365A1 (de) |
CY (1) | CY1107539T1 (de) |
DE (1) | DE60121931T2 (de) |
DK (1) | DK1274692T3 (de) |
ES (1) | ES2267748T3 (de) |
IL (2) | IL151626A0 (de) |
MX (1) | MXPA02009891A (de) |
NO (1) | NO324471B1 (de) |
NZ (1) | NZ521421A (de) |
PT (1) | PT1274692E (de) |
SI (1) | SI1274692T1 (de) |
WO (1) | WO2001077085A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1194418A1 (de) * | 1999-06-21 | 2002-04-10 | Boehringer Ingelheim Pharma KG | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
JP2003525897A (ja) | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
NZ523702A (en) | 2000-08-21 | 2004-08-27 | Astrazeneca Ab | Quinazoline derivatives |
EP1326859A1 (de) | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Chinazoline derivate mit aktivität gegen tumore |
AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
ATE409185T1 (de) | 2001-04-19 | 2008-10-15 | Astrazeneca Ab | Chinazolin derivate |
RU2362775C1 (ru) * | 2002-02-01 | 2009-07-27 | Астразенека Аб | Хиназолиновые соединения |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
EP1521747B1 (de) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Modulatoren von rezeptor-typ-kinase und anwendungsverfahren |
RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
WO2004056812A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
US7223749B2 (en) * | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
DE10326186A1 (de) * | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
JP2007514769A (ja) * | 2003-12-18 | 2007-06-07 | シーブイ・セラピューティクス・インコーポレイテッド | 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 |
WO2005080352A2 (en) * | 2004-02-19 | 2005-09-01 | Rexahn Corporation | Quinazoline derivatives and therapeutic use thereof |
JPWO2005090332A1 (ja) * | 2004-03-23 | 2008-01-31 | 萬有製薬株式会社 | 置換キナゾリン又はピリドピリミジン誘導体 |
DK1746999T3 (da) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
CA2603204A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EP1948179A1 (de) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Chinazolin-derivate zur behandlung von krebserkrankungen |
BRPI0717586A2 (pt) * | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
ES2392639T3 (es) | 2008-02-07 | 2012-12-12 | Boehringer Ingelheim International Gmbh | Heterociclos espirocíclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparación |
MX2010012442A (es) | 2008-05-13 | 2011-10-11 | Astrazeneca Ab | Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina. |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DK2451445T3 (da) | 2009-07-06 | 2019-06-24 | Boehringer Ingelheim Int | Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens |
CN102060875B (zh) * | 2009-11-18 | 2014-03-12 | 天津药物研究院 | 喹唑啉衍生物、制备方法和用途 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
CN105153047A (zh) * | 2015-08-25 | 2015-12-16 | 佛山市赛维斯医药科技有限公司 | 含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途 |
BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
CN106083836B (zh) * | 2016-06-26 | 2021-08-20 | 徐州医学院 | 基于喹唑啉结构的h2s供体化合物及其应用 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE317376B (de) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
US3266990A (en) | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
US3870725A (en) | 1971-03-30 | 1975-03-11 | Lilly Industries Ltd | Nitrothiazole derivatives |
JPS542327A (en) | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
GB2160201B (en) | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
EP0326307B1 (de) | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
EP0572437B1 (de) | 1991-02-20 | 1995-04-26 | Pfizer Inc. | 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen |
AU1422392A (en) | 1991-03-22 | 1992-10-21 | Nippon Soda Co., Ltd. | 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
EP0597003A1 (de) | 1991-08-02 | 1994-05-18 | Pfizer Inc. | Chimoline derivate als immunostimulierende mittel |
GB9127252D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
US5270466A (en) | 1992-06-11 | 1993-12-14 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
RU2137762C1 (ru) | 1994-02-23 | 1999-09-20 | Пфайзер Инк. | 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (de) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
AU5108196A (en) | 1995-03-20 | 1996-10-08 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
EP0824525B1 (de) | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Chinazolin derivate |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
TW334434B (en) | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
KR19990082463A (ko) * | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
NZ332119A (en) * | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
DE19614718A1 (de) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
AU733551B2 (en) | 1996-09-25 | 2001-05-17 | Astrazeneca Ab | Qinoline derivatives inhibiting the effect of growth factors such as VEGF |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (de) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazolinderivate |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
JP4959049B2 (ja) | 1997-08-22 | 2012-06-20 | アストラゼネカ・ユーケイ・リミテッド | 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体 |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP2003525897A (ja) | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1309587B1 (de) | 2000-08-09 | 2008-12-31 | AstraZeneca AB | Cinnoline verbindungen |
CN1315822C (zh) | 2000-08-09 | 2007-05-16 | 阿斯特拉曾尼卡有限公司 | 具有vegf抑制活性的喹啉衍生物 |
JP2004505965A (ja) | 2000-08-09 | 2004-02-26 | アストラゼネカ アクチボラグ | 化合物 |
GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
RU2362775C1 (ru) | 2002-02-01 | 2009-07-27 | Астразенека Аб | Хиназолиновые соединения |
NZ537753A (en) | 2002-08-09 | 2008-04-30 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
-
2001
- 2001-04-03 EP EP01921530A patent/EP1274692B1/de not_active Expired - Lifetime
- 2001-04-03 CN CNB018106846A patent/CN1240688C/zh not_active Expired - Fee Related
- 2001-04-03 IL IL15162601A patent/IL151626A0/xx active IP Right Grant
- 2001-04-03 DK DK01921530T patent/DK1274692T3/da active
- 2001-04-03 NZ NZ521421A patent/NZ521421A/en unknown
- 2001-04-03 AT AT01921530T patent/ATE334973T1/de not_active IP Right Cessation
- 2001-04-03 KR KR1020027013364A patent/KR100858069B1/ko not_active IP Right Cessation
- 2001-04-03 CA CA002403365A patent/CA2403365A1/en not_active Abandoned
- 2001-04-03 SI SI200130631T patent/SI1274692T1/sl unknown
- 2001-04-03 US US10/240,658 patent/US7160889B2/en not_active Expired - Fee Related
- 2001-04-03 WO PCT/GB2001/001514 patent/WO2001077085A1/en active IP Right Grant
- 2001-04-03 MX MXPA02009891A patent/MXPA02009891A/es active IP Right Grant
- 2001-04-03 PT PT01921530T patent/PT1274692E/pt unknown
- 2001-04-03 BR BR0109828-4A patent/BR0109828A/pt not_active IP Right Cessation
- 2001-04-03 ES ES01921530T patent/ES2267748T3/es not_active Expired - Lifetime
- 2001-04-03 AU AU48507/01A patent/AU779695B2/en not_active Ceased
- 2001-04-03 DE DE60121931T patent/DE60121931T2/de not_active Expired - Lifetime
- 2001-04-03 JP JP2001575560A patent/JP4970689B2/ja not_active Expired - Fee Related
-
2002
- 2002-09-05 IL IL151626A patent/IL151626A/en not_active IP Right Cessation
- 2002-10-03 NO NO20024763A patent/NO324471B1/no not_active IP Right Cessation
-
2006
- 2006-11-01 CY CY20061101562T patent/CY1107539T1/el unknown
- 2006-11-17 US US11/600,752 patent/US20070066633A1/en not_active Abandoned
-
2012
- 2012-02-23 JP JP2012037026A patent/JP2012136537A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU779695B2 (en) | 2005-02-10 |
CA2403365A1 (en) | 2001-10-18 |
JP2012136537A (ja) | 2012-07-19 |
CN1240688C (zh) | 2006-02-08 |
BR0109828A (pt) | 2002-12-17 |
KR20020084295A (ko) | 2002-11-04 |
SI1274692T1 (sl) | 2006-12-31 |
NO324471B1 (no) | 2007-10-29 |
DE60121931D1 (de) | 2006-09-14 |
NZ521421A (en) | 2004-09-24 |
AU4850701A (en) | 2001-10-23 |
NO20024763D0 (no) | 2002-10-03 |
EP1274692B1 (de) | 2006-08-02 |
ES2267748T3 (es) | 2007-03-16 |
MXPA02009891A (es) | 2003-03-27 |
US7160889B2 (en) | 2007-01-09 |
KR100858069B1 (ko) | 2008-09-22 |
PT1274692E (pt) | 2006-11-30 |
US20030191308A1 (en) | 2003-10-09 |
JP2003530387A (ja) | 2003-10-14 |
IL151626A (en) | 2008-06-05 |
US20070066633A1 (en) | 2007-03-22 |
CY1107539T1 (el) | 2013-03-13 |
CN1433405A (zh) | 2003-07-30 |
DK1274692T3 (da) | 2006-10-30 |
NO20024763L (no) | 2002-11-19 |
IL151626A0 (en) | 2003-04-10 |
WO2001077085A1 (en) | 2001-10-18 |
EP1274692A1 (de) | 2003-01-15 |
DE60121931T2 (de) | 2007-03-01 |
JP4970689B2 (ja) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE334973T1 (de) | Chinazolinverbindungen | |
DE60322267D1 (de) | Chinolinderivate als glucokinase liganden | |
ATE296826T1 (de) | Pyrazolo(1,5)pyridinderivate | |
ES2128092T3 (es) | Derivados de anilina. | |
DE69011318D1 (de) | Diazinderivate als Angiotensin II Rezeptor Antagonisten. | |
IS6658A (is) | Ný efnasambönd | |
BRPI0411365A (pt) | derivados de aminopiridina | |
DE60129222D1 (de) | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 | |
ATE316083T1 (de) | Adamantanderivate | |
DE69918422D1 (de) | Phthalazinone pde iii/iv hemmer | |
PT1263725E (pt) | Novos compostos | |
ATE321038T1 (de) | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren | |
ES2243579T3 (es) | Derivados de pirazolopirideno. | |
ATE409185T1 (de) | Chinazolin derivate | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
EE200000472A (et) | Kasvajavastased toimeained | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
ES2104174T3 (es) | Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos. | |
ATE274513T1 (de) | Verbindungen und verfahren zur behandlung von schmerz | |
CY1106472T1 (el) | Η χρηση των παραγωγων υδροξυπυριδονης στην επουλωση πληγων | |
DE60013515D1 (de) | 4-Arylpiperidinderivate zur Behandlung von Pruritus | |
DE60215947D1 (de) | Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht | |
ATE327240T1 (de) | 2ß OXO-VORUSCHARIN UND DERIVATEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1274692 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |